Cite

    Cohen, S. B., Alonso-Ruiz, A., Klimiuk, P. A., Lee, E. C., Peter, N., Sonderegger, I., & Assudani, D. (2018). similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study. Annals of the rheumatic diseases, 77(6), 914–921. http://access.bl.uk/ark:/81055/vdc_100150407604.0x00005c